ClinicalTrials.gg
WithdrawnNCT01306994FSS-EDICT IUpdated Jun 6, 2022

Study of Resting and Exercising Body Functioning in Freeman-Sheldon Syndrome and Related Conditions

An observational study in Arthrogryposis and Craniofacial Abnormalities, sponsored by Freeman-Sheldon Research Group, Inc.. Withdrawn at 1 site in United States. Per ClinicalTrials.gov, last updated 2022-06-06.

Sponsored by Freeman-Sheldon Research Group, Inc. · Observational

Why this study was withdrawn
Lack of patient interest
Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
0
Sex
All
01

Study summary

The hypotheses of the present study of Freeman-Sheldon syndrome (FSS) and related conditions are: (1) that exercise capacity is lower in FSS patients versus normal controls, and the lower exercise capacity is due to changes in the muscles' normal structure and an inability of sufficient quantity of the energy molecule to bind to muscle; (2) this muscle problem reduces amount of air that can get in the lung and amount of oxygen carried in the blood, which then has the effect of increasing heart and respiration rates, blood pressure, and deep body temperature, and produces muscle rigidity; (3) the events noted above, when they occur during cardiac stress testing, are related to a problem similar to malignant hyperthermia (MH) reported in some muscle disorders without use of drugs known to cause MH. MH (a life-threatening metabolic reaction that classically is triggered when susceptible persons receive certain drugs used in anaesthesia.

Read the detailed description

This study is a research project initiated by the graduate research student (Mikaela I. Poling) and assisted by the clinical genetics fellow and graduate student (Andrés Morales) in partial fulfilment the requirements for their Masters degrees in Clinical and Applied Physiology, under approval, direction, and supervision of the study PI (Rodger J. McCormick).

Importance of Present Study:

FSS is a rare human neuromusculoskeletal disorder present before birth, involving primarily limb and craniofacial deformities. There are no prospective studies addressing physiological parameters, which are necessary to enable understanding of the underlying pathology and pathophysiology of Freeman-Sheldon syndrome. Elucidating any deviations in baseline and stress physiological parameters in FSS patients versus standard normal values and normal control subjects is of critical importance in tailoring therapeutic interventions to this challenging patient population.

Background:

Vanek et al. (1986) purposed FSS spectrum is a non-progressive congenital myopathy, giving pathological and electromyographical (EMG) evidence. They found white fibrose tissue within histologically normal muscle fibres, resulting in abnormal EMGs.

Toydemir et al. (2006) showed that mutations in embryonic myosin heavy chain 3 (MYH3), caused classic FSS phenotype, in which they screened 28 probands. In 20 patients, new missense mutations caused substitution of arginine at position 672 (arg672) by histidine or cytosine; arg672 is found in all myosin proteins post-embryonically. Of the remaining six patients in whom mutations were found, three had new missense or familial mutations; three other patients with sporadic expression had new, which were also found in Sheldon-Hall syndrome (SHS); two patients had no recognized mutations. They postulated these allelic variations at arg672 could affect adenosine triphosphate (ATP) binding. It is unknown how these mutations might correlate to the phenotypes observed. Their laboratory, including Stevenson et al. (2006) also presented strong evidence that FSS and SHS and similar distal arthrogryposes (DA) were distinct entities based on phenotype, natural history, and genotype.

Portillo et al. (unpublished data), in study of biopsies from their patient, found no evidence of muscle in the superior orbicularis oculi and found highly variable fibre size as a single pathological feature in a single vastus lateralis biopsy. Clinically, their patient, who had to-date the most severe expression of FSS, exhibited no function of the superior eyelid and reasonable muscle tone, bulk, and strength in the thigh. These findings suggested variable syndromic affectation by body region. They reported exertional dyspnea and resting tachycardia, without pathological features, in their patient and anecdotal information concerning exertional dyspnea in two other adult FSS patients. They also documented the occurrence of unexplained, seemingly stress-induced, episodic fever in their patient that resembled the malignant hyperthermia (MH) clinical triad of hyperthermia, tachycardia, and muscle rigidity.

In addition to age, gender, physical activity status, and concomitant disease and disability, maximal oxygen uptake, a function of exercise capacity, is genetically-controlled, and as already documented in other muscle disorders, the idiopathic febrile episodes reported by Portillo et al. may share physiological and biochemical similarities to the well-defined congenital muscle anomaly MH, which classically occurs when susceptible individuals receive inhaled anaesthetics, such as ether and halothane, or depolarizing muscle relaxants during surgery. Together, these clinical observations suggested there may be some syndromic relationship to exercise capacity and development of MH-like febrile syndrome, and it will be important to demonstrate these findings in a controlled experimental setting.

Significant differences among the similar distal arthrogryposes (DAs) may exist, with respect to the above, and this will be important to define experimentally, as well. Data concerning baseline and stress physiology in FSS and similar DAs could help to further define the distinct DA phenotypes clinically similar to FSS, contributing to nosological classification of FSS and related entities. This study will include FSS, Sheldon-Hall syndrome, DA type 1, and DA type 3.

02

Conditions studied

  • Arthrogryposis
  • Craniofacial Abnormalities

Keywords

  • Exercise Test
  • Bicycle Ergometry Test
  • Stress Test
03

In context

Arthrogryposis

16 studies on the registry are indexed under Arthrogryposis; 5 are open to participants now.

Browse Arthrogryposis studies →

Lead sponsor

Freeman-Sheldon Research Group, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Patients world-wide are welcome, so-long as they have a qualifying diagnosis. Healthy controls are welcome world-wide, as well.

Eligibility criteria

Syndrome Group Inclusion Criteria:

  • Freeman-Sheldon syndrome,
  • Sheldon-Hall syndrome,
  • Distal arthrogryposis type 1, or
  • Distal arthrogryposis type 3
  • Deceased patients with enough clinical information available to satisfy study requirements

Syndrome Group Exclusion Criteria:

  • Individuals not confirmed to have a condition under study
  • Deceased patients without enough clinical information available to satisfy study requirements
  • Patients with other anomalies, not having one of the above syndromes
  • Patients or parents of minor children not willing to give consent
  • Mature female patients who are pregnant or breast-feeding will be reassessed for consideration for enrolment.
  • Mature female patients who are currently experiencing menses will be reassessed for consideration for enrolment.
  • Patients with active, acute comorbid illness will be reassessed for consideration for enrolment.

Control Group Inclusion Criteria:

  • Subjects must be healthy and free of active disease.
  • Subject or parent of minor child must be willing to give consent.
  • Subjects must fall within the age-bracket to be matched with a Syndrome Group patient already screened and enroled in the study
  • Subjects must be non-tobacco users and non-drinkers.

Control Group Exclusion Criteria:

  • Subjects exceptional for their age in body weight, stature, or habitus according to commonly accepted guidelines
  • Subjects with active psychiatric illness, as manifested by abnormal mental status examination
  • Subjects with active physical illness, especially respiratory or cardiac problem, as manifested by abnormal findings on physical examination
  • Subjects with significant diagnosis of a constitutional disease or genetic disorder
  • Subjects with a history of severe trauma resulting in either an anatomical of physiological deformity that impairs function
  • Non-living subjects
  • Candidates who fail the stress test
  • Mature female subjects who are pregnant or breast-feeding will be reassessed for consideration for enrolment.
  • Mature female subjects who are currently experiencing menses will be reassessed for consideration for enrolment.
  • Subjects with active, acute illness will be reassessed for consideration for enrolment.
  • Any other condition or anomaly expected to affect current physiology listed in AFI-48-123.
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
0 participants (actual)
Biospecimen retention
None retained

Groups and cohorts

  • Syndrome Group

    Individuals with Freeman-Sheldon, Sheldon-Hall, distal arthrogryposis type 1, or distal arthrogryposis type 3

    Other: Lactate, Glucose, and Adenosine Triphosphate Blood Levels · Procedure: Physiological Stress Test · Other: Functional Enquiry Form · Other: Strength, Joint ROM, Girth and Length Measurements · Other: Study Physical Examination · Other: Observational Gait Analysis · Other: Mental Health Interview

  • Control Group

    Healthy individuals

    Other: Lactate, Glucose, and Adenosine Triphosphate Blood Levels · Procedure: Physiological Stress Test · Other: Functional Enquiry Form · Other: Strength, Joint ROM, Girth and Length Measurements · Other: Study Physical Examination · Other: Observational Gait Analysis · Other: Mental Health Interview

Interventions

  • OtherLactate, Glucose, and Adenosine Triphosphate Blood Levels

    Completed during the clinical examination and exercise test by the researchers, lactate, glucose, and free and total adenosine triphosphate blood levels are determined at rest and during exercise.

    Also known as: ATP levels, ATP blood levels, adenosine triphosphate test, blood test for ATP, blood test for adenosine triphosphate, ATP blood test, adenosine triphosphate blood test, ATP test, glucose test, glucose blood test, sugar test, lactic acid levels, lactic acid blood test, lactate blood test, lactate levels

  • ProcedurePhysiological Stress Test

    During exercise, heart and lung function are monitored for changes caused by exercise, which increases the body's need for oxygen and puts extra demands on the heart. In this study, testing is done using a cycle ergometer and conducted according to the standardised exponential exercise protocol (STEEP).

    Also known as: stress test, graded exercise test, maximal exercise test, VO2 max test, maximal oxygen uptake test, exercise tolerance test, exercise stress test

  • OtherFunctional Enquiry Form

    Evaluated before clinical examination, it is a checklist of medical problems.

    Also known as: FSRG Form 08, health history, review of systems, systems review, medical history, personal health history

  • OtherStrength, Joint ROM, Girth and Length Measurements

    Completed during the clinical examination by the researchers, it is a structured approach to evaluation of muscles, joints, arms, thighs, and legs.

    Also known as: SF 527, Standard Form 527, musculoskeletal examination, musculoskeletal exam, musculoskeletal evaluation, musculoskeletal assessment, extremity examination, extremity evaluation, extremity assessment, extremity exam

  • OtherStudy Physical Examination

    Completed during the clinical examination by the researchers, it is a structured approach to a full physical examination (minus breasts, genitalia, or rectum).

    Also known as: FSRG Form 14, physical examination, physical evaluation, physical assessment, medical examination, medical evaluation, medical assessment, full medical examination, full medical evaluation, full medical assessment, periodic medical examination, periodic medical evaluation, periodic medical assessment, annual medical examination, annual medical evaluation, annual medical assessment, yearly medical examination, yearly medical evaluation, yearly medical assessment, full physical examination, full physical evaluation, full physical assessment, complete physical examination, complete physical evaluation, complete physical assessment, yearly physical examination, yearly physical evaluation, yearly physical assessment, annual physical examination, annual physical evaluation, annual physical assessment, periodic physical examination, periodic physical evaluation, periodic physical assessment, screening physical examination, screening physical evaluation, screening physical assessment, screening physical, physical, periodic physical, annual physical, annual check-up, annual check up, yearly physical, yearly check up, yearly check-up, check up, check-up, medical check-up, medical check up, annual medical check-up, annual medical check up, yearly medical check-up, yearly medical check up, periodic medical check-up, periodic medical check up, periodic health evaluation, periodic health assessment, annual health evaluation, annual health assessment, yearly health evaluation, yearly health assessment, screening health evaluation, screening health assessment, screening medical examination, screening medical evaluation, screening medical assessment, med check

  • OtherObservational Gait Analysis

    Completed during the clinical examination by researchers, it is a structured approach to evaluation of a person's walking.

    Also known as: FSRG 10, gait analysis, functional gait analysis

  • OtherMental Health Interview

    Completed during the clinical examination by the researchers, it is a general evaluation of mental health status.

    Also known as: psychiatric examination, psychiatric evaluation, psychiatric assessment, psychiatric interview, diagnostic mental health examination, diagnostic mental health evaluation, diagnostic mental health assessment, diagnostic psychiatric examination, diagnostic psychiatric evaluation, diagnostic psychiatric assessment, diagnostic psychiatric interview, intake examination, intake evaluation, intake assessment, intake interview, mental health evaluation, mental health examination, mental health assessment, psychological examination, psychological evaluation, psychological assessment, psychological interview, psychological intake examination, psychological intake evaluation, psychological intake assessment, psychological intake interview

06

What researchers measure

Primary outcomes

  1. Heart rate

    Increased heart rate, measured electrocardiographically, is used as an index of cardiovascular strain imposed by needs during exercise and exaggerated by Freeman-Sheldon and related conditions.

    Time frame: Evaluated at rest and while exercising, during two study visits (lasting an average of 1-3 hours)

  2. Oxygen Consumption

    Oxygen consumption, measured by ventilation of expired oxygen, is used as a measure of physiological strain imposed by metabolic needs during exercise and exaggerated by Freeman-Sheldon and related conditions.

    Time frame: Evaluated at rest and while exercising, during two study visits (lasting an average of 1-3 hours)

Secondary outcomes

  1. Non-Invasive Arterial Blood Pressure

    Increased non-invasive arterial blood pressure rate is used as an index of cardiovascular strain imposed by needs during exercise and exaggerated by Freeman-Sheldon and related conditions.

    Time frame: Evaluated at rest and while exercising, during two study visits (lasting an average of 1-3 hours)

  2. Spirometry (Forced Expiratory Volume/Forced Vital Capacity)

    Decreased ability of the lungs to move air, measured by forced expiration, is used as an index of strain imposed by Freeman-Sheldon syndrome and related conditions.

    Time frame: Evaluated before and after exercise, during two study visits (lasting an average of 1-3 hours)

  3. Saturation of Peripheral Oxygen

    Decreased saturation of peripheral oxygen, measured by pulse oxymetry, is used as a measure of physiological strain imposed by metabolic needs during exercise and exaggerated by Freeman-Sheldon and related conditions.

    Time frame: Evaluated at rest and while exercising, during two study visits (lasting an average of 1-3 hours)

  4. Respiratory Rate

    Increased respiratory rate, measured by plethysmograph, is used as a measure of physiological strain imposed by metabolic needs during exercise and exaggerated by Freeman-Sheldon and related conditions.

    Time frame: Evaluated at rest and while exercising, during two study visits (lasting an average of 1-3 hours)

  5. Heart Rhythm

    Heart rhythms, monitored by electrocardiograph, are used as an index of cardiovascular strain imposed by needs during exercise and exaggerated by Freeman-Sheldon and related conditions.

    Time frame: Evaluated at rest and while exercising, during two study visits (lasting an average of 1-3 hours)

  6. Core Temperature

    Increased core temperature, measured as oesophageal temperature, is used as a measure of physiological strain imposed by metabolic needs during exercise and exaggerated by Freeman-Sheldon, related conditions, and malignant hyperthermia.

    Time frame: Evaluated at rest and while exercising, during two study visits (lasting an average of 1-3 hours)

  7. Adenosine Triphosphate

    Decreased adenosine triphosphate, measured as capillary blood level, is used as a measure of physiological strain imposed by metabolic needs during exercise and exaggerated by Freeman-Sheldon and related conditions.

    Time frame: Evaluated at rest and while exercising, during two study visits (lasting an average of 1-3 hours)

  8. Perceived Exertion

    Increased perceived exertion, measured using the Borg scale, are used as an index of fatigue.

    Time frame: Evaluated at rest and while exercising, during two study visits (lasting an average of 1-3 hours)

  9. Muscle Rigidity

    Increased muscle rigidity, evaluated by clinical examination and patient self-report, is used as an indicator of malignant hyperthermia, when increased core temperature, heart rate, and respiratory rate are present.

    Time frame: Evaluated while exercising, during second of two study visits (lasting an average of 1-3 hours)

  10. Functional and Health-Related Quality of Life

    Functional and health-related quality of life, measured with the Medical Outcomes Trust Short Form (36) Health Survey (SF-36), is used as a general prediction of expected physical exercise capacity.

    Time frame: Evaluated in first of two study visits, lasting an average of 1-3 hours

  11. Lactic Acid

    Lactic acid, measured by capillary blood level, is used as a measure of physiological strain imposed by metabolic needs during exercise and exaggerated by Freeman-Sheldon and related conditions.

    Time frame: Evaluated at rest and while exercising, during two study visits (lasting an average of 1-3 hours)

  12. Glucose

    Glucose, measured by capillary blood level, is used as an index of physiological strain, together with lactic acid and adenosine triphosphate capillary blood levels, imposed by metabolic needs during exercise and exaggerated by Freeman-Sheldon and related conditions.

    Time frame: Evaluated at rest and while exercising, during two study visits (lasting an average of 1-3 hours)

Other outcomes

  1. Body Composition

    Body composition, measured by calliper, together with direct indices of physiological strain, is used to determined metabolic disease burden of Freeman-Sheldon syndrome and related conditions.

    Time frame: Evaluated before exercise, during two study visits (lasting an average of 1-3 hours)

  2. Hand Grip Strength

    Decreased hand grip strength, measured by a hand dynamometer, is used as an index of physiological strain imposed by Freeman-Sheldon and related conditions

    Time frame: Evaluated during the first of two study visits

07

Study locations

1 site
  • Freeman-Sheldon Research Group, Inc. Headquarters
    Buckhannon, West Virginia 26201, United States
08

References and documents

Publications

  • Vanek J, Janda J, Amblerova V, Losan F. Freeman-Sheldon syndrome: a disorder of congenital myopathic origin? J Med Genet. 1986 Jun;23(3):231-6. doi: 10.1136/jmg.23.3.231. PubMed 3723551 ↗
  • Toydemir RM, Rutherford A, Whitby FG, Jorde LB, Carey JC, Bamshad MJ. Mutations in embryonic myosin heavy chain (MYH3) cause Freeman-Sheldon syndrome and Sheldon-Hall syndrome. Nat Genet. 2006 May;38(5):561-5. doi: 10.1038/ng1775. Epub 2006 Apr 16. PubMed 16642020 ↗
  • Stevenson DA, Carey JC, Palumbos J, Rutherford A, Dolcourt J, Bamshad MJ. Clinical characteristics and natural history of Freeman-Sheldon syndrome. Pediatrics. 2006 Mar;117(3):754-62. doi: 10.1542/peds.2005-1219. PubMed 16510655 ↗
  • Portillo AL, Chamberlain RL, McCormick RJ, Poling MI. Histopathological and Operative Findings in a Severe Case of Freeman-Sheldon Syndrome: Implications for Nosology and Therapy. (Unpubl.) 2010.
  • Litman RS, Rosenberg H. Malignant hyperthermia: update on susceptibility testing. JAMA. 2005 Jun 15;293(23):2918-24. doi: 10.1001/jama.293.23.2918. PubMed 15956637 ↗
  • McCormick RJ. A Proposal for a Thesis: Heat Tolerance in Exercising Lean and Obese Middle-Aged Men. DEd diss., the Pennsylvania State University, 1973.
  • Myhill S, Booth NE, McLaren-Howard J. Chronic fatigue syndrome and mitochondrial dysfunction. Int J Clin Exp Med. 2009;2(1):1-16. Epub 2009 Jan 15. PubMed 19436827 ↗
  • Northridge DB, Grant S, Ford I, Christie J, McLenachan J, Connelly D, McMurray J, Ray S, Henderson E, Dargie HJ. Novel exercise protocol suitable for use on a treadmill or a bicycle ergometer. Br Heart J. 1990 Nov;64(5):313-6. doi: 10.1136/hrt.64.5.313. PubMed 2245110 ↗
  • Franklin B, Fern A, Fowler A, Spring T, Dejong A. Exercise physiologist's role in clinical practice. Br J Sports Med. 2009 Feb;43(2):93-8. doi: 10.1136/bjsm.2008.055202. Epub 2008 Dec 2. PubMed 19050005 ↗

Individual participant data

Plan to share: No — We do not intend to share any individual participant data.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2014 to primary completion in Jun 2022, 99 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2011
First posted
Mar 2, 2011
StartActual
Mar 2014
Primary completionActual
Jun 2022
CompletionActual
Jun 2022
Last update
Jun 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01306994
Lead sponsor
Freeman-Sheldon Research Group, Inc.
Responsible party
Sponsor
First posted
Mar 2, 2011
Start date
Mar 2014
Primary completion
Jun 2022
Completion
Jun 2022
Last update
Jun 6, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion